Objective: Astroglial-derived protein S100B is known to play important roles in axonal growth, neural plasticity, and energy regulation. Disturbance of these neurodevelopmental processes is proposed as one possible etiology for mood disorder. Therefore, we performed a genetic analysis of S100B in patients with major depressive disorder (MDD).
A fflicting about 3% to 5% of the population worldwide, MDD is a common psychiatric disease. Once the disease develops, episodes tend to recur throughout life. The etiologic foundations remain unknown, although decades of research on neurobiochemistry, neuropathology, and psychopharmacology have made great progress. Family, twin, and adoption studies on depression have provided evidence for the involvement of genetic factors, suggesting that heritable factors play an important role in the etiology of depression. [1] [2] [3] S100B is a calcium-binding protein, which is produced primarily by astrocytes. 4 S100B is the most abundant member of the S100 family in the central nervous system in mammals and is found at concentrations 30-to 100-fold higher in the brain than in other tissues. In vitro experiments show that S100B is involved in the regulation of energy metabolism in brain cells. 4, 5 It modulates the proliferation and differentiation of neurons and glia. 6 The S100B gene has been mapped to 21q22.3, which is a risk region for Down syndrome. 7, 8 It has been reported that a susceptibility gene for affective disorder is probably located in chromosome 21q22.3, on the basis of linkage analysis in one large family. [9] [10] [11] [12] This suggested the location of a susceptibility gene for affective disorder close to where S100B gene is located.
In addition, it is suggested that the 5-beta hydroxytryptamine receptor 1, which stimulates astrocytes, can increase the release of astrocytic nutrition factors (including S100B), and then S100B promotes development of serotonin neurons. 13, 14 Indeed, there is some ongoing debate about the ability of the S100B to promote serotonergic growth. 15 Possibly, the neurite growth is observed in vitro, but this is not clearly observed in vivo. 16 The functional deficiency of growth factors produced by glial cells leads to a weakening of synaptic strength, which could potentially cause depression. For example, Pezet and Maleangio 17 indicated that growth factors (such as brain-derived neurotrophic factor) promoted survival and differentiation of certain neuronal populations during development. In adulthood, brain-derived neurotrophic factor can modulate neuronal synaptic strength and has been implicated in hippocampal mechanisms of learning and memory and spinal mechanisms for pain; several central nervous system disorders such as depression and Alzheimer disease were associated with a decrease in trophic support. 17 It was also found that the antidepressant fluoxetine increased the content of neurotrophic protein S100B in the rat hippocampus. 18 Moreover, it has been demonstrated that the level of S100B in serum or cerebrospinal fluid is changeable in psychiatric disorders, 19 especially in MDD. 20, 21 This evidence suggests that S100B play an important role in depression. All of these observations point to the S100B gene as a candidate for susceptibility to depression. In addition, several investigators have reported the relation between S100B gene polymorphism and several neuropsychiatric disorders including schizophrenia 22 and BPAD. 23 Liu et al 22 found that there was an association of the S100B gene with schizophrenia; that is, what they had established in this work was an association between schizophrenia and S100B haplotype that possibly increased susceptibility to this disorder. Roche et al 23 demonstrated that S100B SNPs rs2839350 and rs3788266 were significantly associated with BPAD. The relation between S100B gene polymorphism and MDD has not been reported. In our study, the 2 SNPs were chosen from the 20 SNPs with more heterozygosis possibility, and were considered for the equilibration in gene distribution of S100B. Therefore, rs9722 at the third exon and rs11911834 at regulatory region were the first 2 of S100B SNPs we chose to perform analysis. Our study examines the possible association between polymorphism of S100B and MDD.
Method

Subjects
A total of 302 people were chosen for the study, and all provided informed consent. The study was approved by the ethics committee of the Second Xiangya Hospital in Central Southern University in Changsha. Complete physical, neurological, and laboratory examinations were performed to show that all patients were free of significant physical and (or) neurological illnesses. All patients and healthy control subjects were Han Chinese in origin.
The patients with MDD (n = 152: 55 men, 97 women; mean age 34.68 years, SD 12.51 years, aged 18 to 58 years) met DSM-IV criteria 24 for a principal diagnosis of unipolar MDD and had a 17-item HDRS total score of 21 or greater; all of them were outpatient clinic patients and inpatients of the Mental Health Institute in the Second Xiangya Hospital. Diagnoses and evaluation of the HDRS and Hamilton Anxiety Rating Scale were carried out by 2 experienced research psychiatrists through semi-structured interviews in conjunction with all other available medical records. Patients who had been examined and given the same depression diagnoses by the 2 psychiatrists were recruited into the study.
Patients with schizophrenia or other psychoses, organic mental disorders, substance dependence, obsessive-compulsive disorder, or any other primary psychiatric disorder were excluded. At the time of testing, all patients were free of major psychotropic drugs for at least 4 weeks (free of fluoxetine for at least 5 weeks). Low-dose benzodiazepines were available for severe agitation and insomnia.
Healthy control subjects (n = 150: 62 men, 88 women; mean age 37.23 years SD 10.28 years, aged 26 to 58 years) were recruited from the Medical Examination Center and Mental Health Institute of the Second Xiangya Hospital, all subjects were reportedly healthy by the Medical Examination Center. Control subjects were considered free of past or present major or minor mental illnesses (such as affective disorder, schizophrenia, anxiety disorder, personality disorder, and substance use disorders). Also, control subjects had no history of psychiatric disorder in their first-degree relatives. Moreover, their HDRS total scores, which were assessed by research psychiatrists, were all less than 7.
Based on data collected by clinical interviews and DSM-IV criteria for MDD, we counted the number of depressive episodes, established the age of onset of the first-depressive episode, and classified 2 or more episodes of depression as recurrent-episode depression (n = 62). We found recurrences and age of onset were not significantly related with the age of MDD by correlation analysis, respectively (P > 0.05). There were no significant differences in sex, age, and BMI in MDD and healthy control subjects (P > 0.05). This suggested that the general characteristics of 2 groups had satisfactory comparability (Table 1) .
Laboratory Method
Genomic DNA was isolated from 5 mL ethylene diamine tetraacetic acid blood samples by trichlormethane methods. The S100B rs9722 polymorphism was determined by PCR-restriction fragment length polymorphism as reported by Jonsson et al. 25 Briefly, according to the websites Entrez Single Nucleotide Polymorphism 26 and Primer3, 27 the primers were designed by us as following: rs9722, L (5¢-ACTACTGCC-TGCCACGAGTT-3¢), and R (5¢-CCGTTAAAAC-AGCCTTTGGA-3); rs11911834, L (5¢-GCATTCTGG GAATTTGCACT-3¢), and R (5¢-TTGCAGTTGATGGTTTGCTC-3¢). The polymorphisms rs9722 and rs11911834 of the S100B gene were determined. By using 100 ng genomic DNA and respective primers, 213 bp and 283 bp fragments were PCR-amplified, respectively. Amplification was performed by GeneAmp PCR system (BIO-RAD, California, United States). PCR conditions were initial denaturation step of 3 minutes at 94°C; 30 cycles of 30 seconds at 94°C, 30 seconds at (rs9722, 55°C; rs11911834, 52°C) and 1 minute at 72°C; final extension step of 5 minutes at 72°C. The rs9722-amplified PCR product (213 bp) was digested with 1.7 units of restriction enzyme TaaI (MBI, Jingmei, Shenzhen, China) for 5 hours at 65°C. The rs11911834-amplified PCR product (283 bp) was digested with 1.7 units of restriction enzyme CfrI (MBI, Jingmei, Shenzhen, China) for 10 hours at 37°C. Digested products were electrophoresed on polyacrylamide gel and then stained with AgNO 3 and photographed. Genotypes of rs9722 and rs11911834 were determined by TaaI digestion (wild C allele: 139 bp + 74 bp, mutant T allele: 241 bp ) and by CfrI digestion (wild G allele: 193 bp + 90 bp, mutant T allele: 283 bp), respectively.
Statistical Analyses
Tests to compare the quantitative variables (for example, age and BMI) between patients with MDD and healthy control subjects were performed by using the independent t test. The Hardy-Weinberg equilibrium and the differences in the genotype and allele frequencies between the groups were tested by using the chi-square test or Fisher exact test. The comparisons of fundamental demography information in 3 genotypes of MDD were analyzed by an analysis of variance test or chi-square test. The statistical package for social science (SPSS [SPSS Inc, Chicago, IL] 11.5 for Windows) was used for the above-mentioned analysis. A difference was considered significant at P < 0.05. With this level of significance, for single marker analyses, the study in our sample had a power of 0.33 to detect a small effect, 0.99 to detect a medium effect, and 0.99 to detect a large effect in a genotype distribution (n = 302). In the allele frequencies (n = 604), this study had a power of 0.69 to detect a small effect, 0.99 to detect a medium effect, and 0.99 to detect a large effect. In this power analysis, effect size conventions were determined according to Cohen's method. 28
Results
We compared the genotype frequencies and allele gene frequencies in rs9722 and rs11911834 of the S100B gene in people with MDD with those in healthy control subjects.
Genotypes and allele frequencies are summarized in Table 2 . Rs9722 and rs11911834 polymorphism genotypes in MDD and healthy control subjects were in line with the Hardy-Weinberg law of equilibrium (P > 0.05). Genotypic frequency of wide-type homozygote (CC), heterozygote (CT), and mutant homozygote (TT) of rs9722 were 0.30, 0.56, and 0.14 in 152 patients with MDDs, and 0.32, 0.53, and 0.15 in 150 healthy control subjects, respectively; C allele frequency was 0.58 in patients and 0.59 in control subjects, while T allele frequency was 0.42 and 0.41, respectively. 29 Genotypic frequency of wide-type homozygote (GG), heterozygote (GT), and mutant homozygote (TT) of rs11911834 were 0.73, 0.23, and 0.04 in patients, and 0.71, 0.22, and 0.07 in control subjects, respectively; G allele frequency was 0.845 in patients and 0.817 in control subjects, while T allele frequency was 0.155 and 0.183, respectively. Table 2 showed that there were no significant differences in the population distribution of genotypes and allele gene by chi-square test (P > 0.05). Table 3 lists the comparisons of fundamental demography information in the rs9722 genotypes wide-type homozygote (CC), heterozygote (CT), and mutant homozygote (TT) of MDD. Quantitative data were analyzed by analysis of variance test, enumeration data by chi-square test, or Fisher exact test. The results showed that there was statistical significance in 2 items, that is, age of onset and depression types (first episode and recurrent episode depression) in the genotypes wide-type homozygote (CC), heterozygote (CT), and mutant homozygote (TT) of MDD (P < 0.05). By using the Kruskal-Wallis test among these 3 genotypes, significant differences were found that the carrying mutant homozygote (TT) genotype patients with MDD were possibly more vulnerable recurrent than those carrying heterozygote (CT). Table 4 listed the comparisons of fundamental demography information in the genotypes wide-type homozygote (GG), heterozygote (GT), and mutant homozygote (TT) of the S100B gene rs11911834 in MDD. Measurement data were analyzed by the analysis of variance test; enumeration data by chi-square test (Fisher exact test). The results showed that there was statistical significance in depression types (first-episode and recurrent episode depression) in the genotypes wide-type homozygote (GG), heterozygote (GT), and mutant homozygote (TT) of S100B gene rs11911834 in MDD (P < 0.05). By using the Kruskal-Wallis test among these 3 genotypes, significant differences were found that the carrying heterozygote (GT) genotype patients with MDD were possibly more vulnerable recurrent than those carrying wide-type homozygote (GG).
Demographic and Clinical Data in 3 Genotypes S100B Gene rs9722 in Depression
Demographic and Clinical Data in 3 Genotypes of S100B Gene rs11911834 in Depression
Discussion
The human S100B gene is composed of 3 exons. The first one specifies the 5¢ untranslated region, while the second and third exons encode a single EF-hand (helix-loop-helix structural domain), Ca2+-binding domain, respectively. The promoter region contains several potential regulatory transcription elements including the cyclic adenosine Values in the parentheses represent percentage of frequency monomphsopate-responsive elements and activator protein-2. 7, 8 In this study, we investigated the relation between 2 polymorphisms of the S100B gene and MDD in Han Chinese patients. The results suggest that there was no possible association between the 2 polymorphisms of S100B gene and MDD.
In the comparison of general demography and clinical phenotypes in rs9722 wide-type homozygote (CC), heterozygote (CT), and mutant homozygote (TT) genotype in patients with depression (Table 3) , we found that there were significant differences in age of onset in 3 genotypes. This study showed that the age of onset in patients with depression with wide-type homozygote (CC) and heterozygote (CT) genotype was higher than in those with mutant homozygote (TT) genotype, and the age in patients with depression of homozygotes carrying T allele was lower than those of homozygotes and heterozygote carrying C allele. It has been reported that there was a close relation between S100B protein and age in depression. Wiesmann et al 30 found that S100B concentrations in cerebrospinal fluid were related with age. With age increasing, the S100B levels were heightened, which was possibly related to the apoptosis of gliocyte, disappearance of medullary sheath, the prolongation of periodicity in cerebrospinal fluid circulation, and changes of metabolism. 30 Sheng et al 31 analyzed the expression of S100B and its encoding messenger ribonucleic acid, and suggested that increased S100B expression may be an important response to age-related changes in brain function. The results of our study suggested that rs9722 polymorphism may be correlated with a subgroup of MDD (early or late onset). The significant differences of onset age in these 3 genotypes distribution showed that the polymorphism of S100B rs9722 seemed to predict the early onset in MDD. Because of the limited sample, we should be prudent about the conclusion, which needs further study.
MDD is a prevalent and chronic psychiatric disorder. Only about 10% to 20% of the cases were reported as only one episode of depression during the 25-year follow-up, and another 10% to 20% were chronic, developing. 32, 33 Most cases exhibited recurrent episodes. Studies indicated that 60% to 80% of adults who experience one episode would undergo at least one recurrence, with most recurrences occurring within the first 5 years. 34 Women may be particularly vulnerable to recurrence. 35 It is possible that clinical differences between recurrent and nonrecurrent cases of MDD could be recognized as risk factors of recurrent depression. 36 Certain clinical features of depressive episodes such as sleep disturbance, the severity of the initial episode, and earlier onset have been identified as predictors of recurrence. 37 Our study found that the polymorphisms of rs9722 and rs11911834 were related to the recurrence of depression. For rs9722, the carrying heterozygote (GT) genotype patients with MDD were possibly more vulnerable to recurrence than those carrying mutant homozygote (TT); for rs11911834, the patients with MDD carrying the heterozygote (GT) genotype were possibly more vulnerable to recurrence than those carrying the wide-type homozygote (GG). Therefore, we will further study the influences of genotypes of S100B gene on the recurrent depression in the future.
However, in our study, about three-fifths of patients had first-episode MDD. Some people in our sample who had not yet had recurrences will likely experience another episode later in their lives. In such cases, we misidentified these people as nonrecurrent, which could confuse neurobiologic differences between single-episode and recurrent depression. In addition, the accuracy of retrospective symptom recall is uncertain. Because of ethnic and methodological differences in an association study, pseudo-positive or negative results appeared possible. Moreover, we could find only one research paper about the association between the polymorphisms of S100B and BPAD. 23 Therefore, an association study between the polymorphisms of S100B gene and MDD in other samples needs to be repeated.
Conclusions
The detailed evaluation of the functional polymorphism of S100B gene at rs9722 and rs11911834 in patients with MDD and control groups suggested that there was significant differences in 3 genotypes distribution in first-episode depression and recurrent MDD, although we found no association between polymorphisms in the S100B gene and MDD in the Han Chinese population. Therefore, further studies using larger sample sizes are needed to investigate the association between the S100B gene and MDD. thank all doctors and nurses who participated in our study in the Second Xiangya Hospital of Central Southern University for their technical assistance. Moreover, we appreciate all patients and healthy control subjects in our study.
